noroxymorphone noroxymorphone noroxymorphone is an opioid which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of narcotic antagonists such as naltrexone and others. it is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity. noroxymorphoneclinical dataroutes ofadministrationintravenous, intramusucular, subcutaneous, oral, rectal, intranasallegal statuslegal status us: schedule ii identifiers iupac name 7,8-dihydro-14-hydroxynormorphinone cas number33522-95-1pubchem cid5497189drugbankdbmet00424chemspider4593755unii9nz7111a9ocomptox dashboard (epa)dtxsid80955145 echa infocard100.046.859 chemical and physical dataformulac16h17no4molar mass287.315 g·mol−13d model (jsmol)interactive image smiles oc1ccc2c3ncc45(oc1c24)c(=o)cc35o inchi inchi=1s/c16h17no4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20h,3-7h2/t11-,14+,15+,16-/m1/s1key:hlmsizpqbsyunl-ipoqpsjvsa-n in the united states, noroxymorphone is controlled as a schedule ii narcotic controlled substance with an acscn of 9637 and in 2014 the dea set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale. in other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.